A practical reference on freeze-thaw cycling: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-07-30. Anything still debated is marked as such rather than presented as settled.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
==== Chronic non-cancer pain ==== Guidelines have suggested that the risks of opioids are likely greater than their benefits when used for most non-cancer chronic conditions including headaches, back pain, and fibromyalgia. Thus they should be used cautiously in chronic non-cancer pain. If used, the benefits and harm should be reassessed at least every three months. For treating chronic pain, opioids are an option after other less risky pain relievers have been considered, including paracetamol or nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or naproxen. Some types of chronic pain, including the pain caused by fibromyalgia or migraine, are preferentially treated with non-opioid drugs. The efficacy of using opioids to lessen chronic neuropathic pain is uncertain. Opioids are contraindicated as a first-line treatment for headache because they impair alertness, bring risk of dependence, and increase the risk that episodic headaches will become chronic. Opioids can also cause heightened sensitivity to headache pain. When other treatments fail or are unavailable, opioids may be appropriate for treating headache if the patient can be monitored to prevent the development of chronic headache. Starting in the late 20th century, there was an increase in the use of opioids in the management of non-malignant chronic pain. This practice has led to a growing problem with addiction and misuse of opioids, the opioid epidemic.
A further derivative of rasagiline, ladostigil ([N-propargyl-(3R)-aminoindan-5-yl]-N-propylcarbamate), a dual MAO-B inhibitor and acetylcholinesterase inhibitor, was developed for treatment of Alzheimer's disease and other conditions but was ultimately never introduced for medical use.
== Combination Therapy - Antibacterial == Photodynamic/photothermal combination therapy combines the mechanisms of ROS production and heat generation into one treatment for a heightened effect on the target bacterial cells. In many cases, this can be done with a single compound or nanomaterial (phototherapeutic agent) and wavelength.
At the end of the twentieth century, the world was at a major crossroads. Throughout the century, more technological advances had been made than in all of preceding history. Computers, the Internet, and other technologies radically altered daily lives. However, several problems faced the world during the Cold War period and the 1990s that followed. First of all, the gap between rich and poor nations continued to widen. Some said that this problem could not be fixed, arguing that there was a set amount of wealth and it could only be shared by so many. Others claimed that powerful nations with large economies were not doing enough to help improve the rapidly evolving economies of the Third World. Developing countries faced many challenges, including the scale of the task to be surmounted, rapidly growing populations, and the need to protect the environment, along with the associated costs. Secondly, disease threatened to destabilize many regions of the world. Viruses such as West Nile and Avian influenza continued to spread quickly and easily. In poor nations, malaria and other diseases affected the majority of the population. Millions were infected with HIV, the virus that causes AIDS, which was becoming an epidemic in southern Africa and around the world. Increased globalization, specifically Americanization, was also occurring. While not necessarily a threat, it was causing anti-Western and anti-American feelings in parts of the world, especially in the Middle East.
Sources: en.wikipedia.org
The half-life, t1/2, is the time taken for the activity of a given amount of a radioactive substance to decay to half of its initial value. The decay constant, λ "lambda", the reciprocal of the mean lifetime (in s−1), sometimes referred to as simply decay rate. The mean lifetime, τ "tau", the average lifetime (1/e life) of a radioactive particle before decay. Although these are constants, they are associated with the statistical behavior of populations of atoms. In consequence, predictions using these constants are less accurate for minuscule samples of atoms. In principle a half-life, a third-life, or even a (1/√2)-life, could be used in exactly the same way as half-life; but the mean life and half-life t1/2 have been adopted as standard times associated with exponential decay. Those parameters can be related to the following time-dependent parameters:
=== Production of ethanolamines === In the industry, ethanolamines (mono-, di-, and triethanolamines) are produced by reacting ammonia and ethylene oxide in anhydrous medium at a temperature of 40–70 °C (100–160 °F) and pressure of 1.5–3.5 MPa (220–510 psi) MPa:
He held a very wide variety of posts, included Member, Governing Body, Royal Academy of Music, 1967–1979, Director, Central Statistical Office, 1968–1978, BBC Music Advisory Committee, 1971–1983, Visiting Fellow, Nuffield College, Oxford, 1972–1980, Chairman, Royal Opera House, Covent Garden, 1974–1987, Director, N M Rothschild & Sons, 1978–1990 (Vice-chairman, 1978–1984), President, Royal Statistical Society, 1978–1980, Chairman, Economist Intelligence Unit, 1979–1983, Warden of Wadham College, Oxford, 1984–1993, Chancellor, Keele University, 1986–2002, Trustee, London Philharmonic Orchestra, 1988–2000, President, British Association for the Advancement of Science, 1989–1990, Pro-Vice-Chancellor, University of Oxford, 1991–1993, Chairman, British Museum Development Trust, 1993–2003, later Chairman Emeritus, Chancellor, Open University of Israel, 1994–2004 Moss, Celia (1819-1873 and Marion (1821-1901), Anglo-Jewish writers and educators, authors of poetry, prose and fiction, Marion Moss Hartog established the first Jewish women's periodical, the Jewish Sabbath Journal: A Penny and Moral Magazine for the Young, which foundered after it was attacked by the Jewish Chronicle.
== Corporate history == KCI was founded in 1976 in San Antonio, Texas, by James R. Leininger, then an emergency room physician who wanted to help prevent the pulmonary complications associated with immobility. Over time, the company developed or acquired a line of therapeutic specialty beds, introducing a specialty bed for acute care patients with pulmonary complications. Initially KCI's product development focused on therapeutic beds and surfaces then expanded to introduce the first commercial negative pressure wound therapy products in the mid-1990s. KCI acquired regenerative medicine company, LifeCell, in 2008 in a non-hostile transaction for US$1.7 billion. In January 2012, LifeCell was made a sister company to KCI. In 2013, LifeCell and KCI recombined into one company.
Although Descartes agreed with the contemporary position, that a vacuum does not occur in nature, the success of his namesake coordinate system and more implicitly, the spatial–corporeal component of his metaphysics would come to define the philosophically modern notion of empty space as a quantified extension of volume. By the ancient definition however, directional information and magnitude were conceptually distinct.
Sources: en.wikipedia.org
While the Cro-Magnons are usually assumed to have generally practised sexual division of labour with men hunting and women gathering such as in the preponderance of recent hunter-gatherer societies, it is unclear to what extent this may be applied to Neanderthals. Both Neanderthal men and women have similar traumatic injury patterns, which might imply that both sexes were involved in hunting. Dental wearing patterns among Neanderthals, on the other hand, could indicate men and women typically carried different items with their mouths, though these may not have been related to subsistence tasks. The women at El Sidrón Cave, Spain, may have been eating more seeds and nuts than the men. The lack of distinctive task specialization in Neanderthals has usually been linked to their small population and group size, falling short of the demographic threshold where task specialization becomes feasible — which may also explain the comparative simplicity of Neanderthal material culture.
Regional differences are seen in the products and bases. The company has localized to Southeast Asia with a baked rice dish called Curry Zazzle. On May 9, 2008, Pizza Hut created "The Natural" pizza, which featured natural ingredients and was sold in Seattle, Denver and Dallas. This was discontinued on October 27, 2009, in the Dallas market. Pizza Hut developed a pizza to be delivered to the International Space Station in 2001. It was vacuum-sealed and about 6 in (15 cm) in diameter to fit in the station's oven. It was launched on a Soyuz and eaten by Yuri Usachov in orbit. In the 2010s, the chain saw a downturn in profits. In 2015, the franchise stated it would be pumping more capital into its London branches. Pizza Hut is installing cocktail bars in its London branches as part of a £60 million bid to win back "the Nando's generation". In January 2019, Pizza Hut announced it had expanded beer delivery to 300 locations across the US., with plans to expand to 1,000 locations by the middle of the year. In March 2019, Pizza Hut announced the return of the P'Zone after a hiatus of several years. In March 2020, Pizza Hut Hong Kong announced that it had partnered with furniture retailer IKEA on a joint venture. IKEA launched a new side table called SÄVA, which was designed to resemble a pizza saver. The table would be boxed in packaging resembling a pizza box, and the building instructions included a suggestion to order a Swedish meatball pizza from Pizza Hut, which would contain the same meatballs served in IKEA restaurants.
=== Other research === In 2001, Sachs led a research team at UB which found that a chemical isolated from the venom of the Chilean tarantula could calm abnormal rhythms induced in rabbit hearts. Sachs said the result of this study showed that the protein could herald a new class of compounds that could be targeted at treating the causes, rather than the symptoms, of atrial fibrillation. Following this discovery, Sachs was named a UB Distinguished Professor and honored by Buffalo Business First for his invention. In 2013, Sachs and his research team identified that familial xerocytosis causes symptoms, such as the shortness of breath seen in anemic patients. This identification marked the first time defects in a mechanosensitive ion channel were implicated as the cause of a disease. Beyond spider venom, Sachs also conducted the first voltage clamp studies of isolated adult heart cells. He was also responsible for the first single-channel recording from tissue cultured cells.
Prolactin-releasing peptide (PrRP) is a peptide hormone that in humans is encoded by the PRLH gene. PrRP binds to the receptor PrRPR and seems to be involved in appetite regulation, but its precise function isn’t fully understood. Though early research suggested that PrRP stimulates prolactin (PRL) release, hence its name, this potential function is debated. Unlike other anterior pituitary hormones, the hypothalamus seems to primarily regulate prolactin release through inhibition, mostly via dopamine as part of the hypothalamic–pituitary–prolactin axis.
Ferdinand II 1564–1595, second son of Emperor Ferdinand I Maximilian III 1612–1618, son Leopold V 1619–1632, younger brother of Emperor Ferdinand II Ferdinand Charles 1632–1662, son, with his mother Claudia de' Medici 1632–1646, as regent Sigismund Francis 1663–1665, brother Line extinct, Habsburg lands re-unified under
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.